Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling

Oncogene

Volumn 35, Issue 42, 2016, Pages 5501-5514

  Li, J ^a   Wu, H ^b   Li, W ^c   Yin, L ^a   Guo, S ^a   Xu, X ^a   Ouyang, Y ^a   Zhao, Z ^a   Liu, S ^a   Tian, Y ^a   Tian, Z ^a   Ju, J ^d   Ni, B ^a   Wang, H ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SOUTHWEST HOSPITAL   (China)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DECITABINE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MICRORNA; MICRORNA 506; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1; TRANSCRIPTION FACTOR RELA; TUMOR MARKER; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN506 MICRORNA, HUMAN; PHOSPHOTRANSFERASE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG TARGETING; ECTOPIC EXPRESSION; EPIGENETICS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; 3' UNTRANSLATED REGION; ANIMAL; BINDING SITE; CELL CYCLE; CELL CYCLE CHECKPOINT; DISEASE COURSE; DISEASE MODEL; DRUG RESISTANCE; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NF-KAPPA B; PANCREATIC NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84963627649     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.90     Document Type: Article

References (47)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008; 3: 157-188.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057.
4. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319-334.
5. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481.
6. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005; 122: 553-563.
7. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
8. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18: 534-545.
9. Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N et al. MicroRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer 2015; 51: 1389-1404.
10. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J et al. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 2014; 146: 268-277 e218.
11. Guo S, Xu X, Tang Y, Zhang C, Li J, Ouyang Y et al. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Cancer Lett 2014; 344: 40-46.
12. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-770.
13. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013; 23: 186-199.
14. Yin M, Ren X, Zhang X, Luo Y, Wang G, Huang K et al. Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-(kappa)B p65 to evoke reactive oxygen species generation and p53 activation. Oncogene 2014; 34: 691-703.
15. Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31: 1558-1570.
16. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008; 9: 662-673.
17. Song L, Xiong H, Li J, Liao W, Wang L, Wu J et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin Cancer Res 2011; 17: 1839-1849.
18. Bracken CP, Khew-Goodall Y, Goodall GJ. Network-based approaches to understand the roles of miR-200 and other microRNAs in cancer. Cancer Res 2015; 75: 2594-2599.
19. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 2014; 33: 514-524.
20. Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene 2015; 34: 1629-1640.
21. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506.
22. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
23. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011; 32: 1183-1189.
24. Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM et al. miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene 2014; 34: 717-725.
25. Arora H, Qureshi R, Park WY. miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One 2013; 8: e64273.
26. Sakimura S, Sugimachi K, Kurashige J, Ueda M, Hirata H, Nambara S et al. The miR-506-induced epithelial-mesenchymal transition is involved in poor prognosis for patients with gastric cancer. Ann Surg Oncol 2015; 22: 1436-1443.
27. Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett 2011; 585: 3560-3568.
28. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 2015; 235: 25-36.
29. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 2014; 233: 308-318.
30. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009; 23: 405-414.
31. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009; 69: 6915-6923.
32. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
33. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012; 72: 726-735.
34. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008; 14: 6996-7003.
35. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15: 1393-1399.
36. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009; 8: 809-820.
37. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
38. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 2012; 109: E1695-E1704.
39. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 2011; 18: 1111-1120.
40. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013; 31: 577.
41. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-1674.
42. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 2015; 112: 1241-1246.
43. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433.
44. Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 2014; 20: 1990-2000.
45. Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 2014; 9: e91551.
46. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F et al. NT5E mutations and arterial calcifications. N Engl J Med 2011; 364: 432-442.
47. Su J, You P, Li WL, Tao XR, Zhu HY, Yao YC et al. The existence of multipotent stem cells with epithelial-mesenchymal transition features in the human liver bud. Int J Biochem Cell Biol 2010; 42: 2047-2055.